不同剂量重组人生长激素对非生长激素缺乏性矮小症患儿生长激素-胰岛素样生长因子轴的影响  

Effects of different doses of recombinant human growth hormone on growth hormone insulin-like growth factor axis in children with non-growth hormone deficient short stature

作　　者：郭莹 刘洋[1] GUO Ying;LIU Yang(Department of Pediatrics,Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology,Wuhan 430022,China)

机构地区：[1]武汉科技大学附属武汉亚心总医院儿科,武汉430022

出　　处：《临床药物治疗杂志》2023年第6期49-52,共4页Clinical Medication Journal

基　　金：武汉市公共卫生及卫生政策科研项目(WG16D16)。

摘　　要：目的 探讨不同剂量重组人生长激素(rhGH)对非生长激素缺乏性矮小症(NGHDSS)患儿生长激素-胰岛素样生长因子轴的影响。方法 选择2020年6月至2021年9月武汉亚心总医院儿科收治的NGHDSS患儿,按随机数字表法分为对照组和观察组。对照组给予小剂量rhGH[0.10 U/(kg·d)]联合营养治疗,观察组给予大剂量rhGH[0.15 U/(kg·d)]联合营养治疗,均连续治疗12个月。比较两组患儿治疗前后身高变化、身高标准差积分(HtSDS)和生长速度(GV),分析治疗前后血清生长激素(GH)、胰岛素样生长因子结合蛋白3(IGFBP-3)及胰岛素样生长因子1(IGF-1)水平变化,观察两组不良反应发生情况差异。结果 治疗后,两组患儿HtSDS[对照组(-1.98±0.19)分,观察组(-1.72±0.16)分]、GV[对照组(6.53±0.85)cm/年,观察组(10.36±1.02)cm/年]、身高[对照组(125.06±3.85) cm,观察组(130.89±3.06)cm]及血清IGF-1[对照组(258.76±99.85)μg/L,观察组(301.30±121.26)μg/L]、IGFBP-3[对照组(6.04±0.42)μg/mL,观察组(7.49±0.91)μg/mL]、GH [对照组(3.51±0.78)μg/L,观察组(5.06±0.92)μg/L]水平均明显升高,且观察组高于对照组,差异有统计学意义(P<0.05)。两组治疗期间不良反应发生情况比较,差异无统计学意义(P>0.05)。结论 大剂量rhGH治疗NGHDSS,可以明显改善其身高和GV,改善生长激素-胰岛素样生长因子轴相关激素的分泌,安全性高,具有一定的临床应用价值。Objective To investigate the effects of different doses of recombinant human growth hormone(rhGH) on growth hormone insulin-like growth factor axis in children with non-growth hormone deficient short stature(NGHDSS).Methods Children with NGHDSS admitted to the Department of Pediatrics of Wuhan Asia General Hospital from June 2020 to September 2021 were divided into control group and observation group by random number table method.The control group was given low-dose rhGH[0.10 U/(kg·d)] combined with nutritional therapy,and the observation group was treated with high-dose rhGH[0.15 U/(kg·d)] combined with nutritional therapy for 12 months.The changes of height,height standard deviation score(HtSDS) and growth rate(GV) before and after treatment were compared between the two groups.The changes of serum growth hormone(GH),insulin-like growth factor binding protein 3(IGFBP-3) and insulin-like growth factor 1(IGF-1) before and after treatment were analyzed,and the differences of adverse reactions between the two groups were observed.Results After treatment,two groups of children with HtSDS [the control group(1.98±0.19) points,observation group(1.72±0.16) points],GV [control group(6.53±0.85) cm/year,observation group(10.36±1.02) cm/year],height [control group(125.06±3.85) cm,observation group(130.89±3.06) cm],serum IGF-1 [control group(258.76±99.85)μg/L,observation group(301.30±121.26)μg/L),IGFBP-3 [control group(6.04±0.42] μg/m L,observation group(7.49±0.91) μg/m L],and GH [control group(3.51±0.78)μg/L,observation group(5.06±0.92)μg/L] levels were significantly increased,and the observation group were higher than these of the control group,the difference were statistically significant(P>0.05).There was no significant difference in the occurrence of adverse reactions between the two groups during treatment(P<0.05).Conclusion High-dose rhGH treatment can significantly improve its height and GV of NGHDSS,and the secretion of growth hormone insulinlike growth factor axis-related hormones,which shows hi

关 键 词：重组人生长激素 非生长激素缺乏性矮小症 生长激素-胰岛素样生长因子轴 

分 类 号：R977.1[医药卫生—药品] R584[医药卫生—药学]